Aberrant expression of neuropilin-1 and-2 in human pancreatic cancer cells

被引:75
作者
Fukahi, K
Fukasawa, M
Neufeld, G
Itakura, J
Korc, M
机构
[1] Univ Calif Irvine, Div Endocrinol Diabet & Metab, Dept Med, Irvine, CA USA
[2] Univ Calif Irvine, Div Endocrinol Diabet & Metab, Dept Biol Chem, Irvine, CA USA
[3] Univ Calif Irvine, Div Endocrinol Diabet & Metab, Dept Pharmacol, Irvine, CA USA
[4] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel
[5] Yamanashi Med Univ, Dept Surg 1, Yamanashi, Japan
关键词
D O I
10.1158/1078-0432.CCR-0930-03
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Neuropilin (Np)-1 and -2 are coreceptors for vascular endothelial growth factor (VEGF). This study was designed to assess their role in pancreatic ductal adenocarcinoma (PDAC). Experimental Design: We assessed Np-1 and Np-2 expression by real-time quantitative PCR in relation to the expression of VEGF ligands and receptors in pancreatic cancer cell lines and tissues. Results: ASPC-1, CAPAN-1, and PANC-1 pancreatic cancer cells and tumor-derived, laser-captured pancreatic cancer cells exhibited higher Np-1 and Np-2 mRNA levels than VEGF receptor-1, -2, or -3 mRNA levels. Transfection of Np-1 and Np-2 cDNAs in COS-7 cells, and treatment with tunicamycin revealed that both proteins were glycosylated. Both proteins were expressed in pancreatic cancer cell lines, in the PDAC samples, and in acinar cells adjacent to the cancer cells. The normal pancreas was devoid of Np-1 immunoreactivity, whereas Np-2 immunoreactivity was present in the endocrine islets and in some acinar cells, but not in ductal cells. Conclusions: The aberrant localization of Np-1 and Np-2 in the cancer cells in PDAC suggests that in addition to exerting proangiogenic effects, these coreceptors may contribute to novel autocrine-paracrine interactions in this malignancy.
引用
收藏
页码:581 / 590
页数:10
相关论文
共 49 条
[1]  
Bachelder RE, 2001, CANCER RES, V61, P5736
[2]  
Baker CH, 2002, CANCER RES, V62, P1996
[3]  
Banerjee SK, 2000, INT J ONCOL, V16, P253
[4]  
Chen Z, 1999, CLIN CANCER RES, V5, P1369
[5]   Neuropilin-2 is a novel marker expressed in pancreatic islet cells and endocrine pancreatic tumours [J].
Cohen, T ;
Herzog, Y ;
Brodzky, A ;
Greenson, JK ;
Eldar, S ;
Gluzman-Poltorak, Z ;
Neufeld, G ;
Resnick, MB .
JOURNAL OF PATHOLOGY, 2002, 198 (01) :77-82
[6]   Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy [J].
Dias, S ;
Choy, M ;
Alitalo, K ;
Rafii, S .
BLOOD, 2002, 99 (06) :2179-2184
[7]   Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma [J].
Ellis, LM ;
Takahashi, Y ;
Fenoglio, CJ ;
Cleary, KR ;
Bucana, CD ;
Evans, DB .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (03) :337-340
[8]   Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia [J].
Enholm, B ;
Paavonen, K ;
Ristimaki, A ;
Kumar, V ;
Gunji, Y ;
Klefstrom, J ;
Kivinen, L ;
Laiho, M ;
Olofsson, B ;
Joukov, V ;
Eriksson, U ;
Alitalo, K .
ONCOGENE, 1997, 14 (20) :2475-2483
[9]   Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and-2 in human neuroblastoma [J].
Fakhari, M ;
Pullirsch, D ;
Abraham, D ;
Paya, K ;
Hofbauer, R ;
Holzfeind, P ;
Hofmann, M ;
Aharinejad, S .
CANCER, 2002, 94 (01) :258-263
[10]   Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene [J].
Ferrara, N ;
CarverMoore, K ;
Chen, H ;
Dowd, M ;
Lu, L ;
OShea, KS ;
PowellBraxton, L ;
Hillan, KJ ;
Moore, MW .
NATURE, 1996, 380 (6573) :439-442